BRPI0618469A2 - hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto - Google Patents

hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto Download PDF

Info

Publication number
BRPI0618469A2
BRPI0618469A2 BRPI0618469-3A BRPI0618469A BRPI0618469A2 BR PI0618469 A2 BRPI0618469 A2 BR PI0618469A2 BR PI0618469 A BRPI0618469 A BR PI0618469A BR PI0618469 A2 BRPI0618469 A2 BR PI0618469A2
Authority
BR
Brazil
Prior art keywords
bone
parathyroid hormone
black bear
methods
bear parathyroid
Prior art date
Application number
BRPI0618469-3A
Other languages
English (en)
Inventor
Seth W Donahue
Original Assignee
Univ Michigan Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan Tech filed Critical Univ Michigan Tech
Publication of BRPI0618469A2 publication Critical patent/BRPI0618469A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/37—Parathyroid hormone [PTH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

HORMÈNIO PARATIRóIDE DE URSO PRETO E MéTODOS DE USO DE HORMÈNIO PARATIRóIDE DE URSO PRETO. O hormónio paratirólde de urso preto (PTH) e fragmentos funcionais são fornecidos aqui. Também fornecidos são métodos de usar PTH de urso preto e fragmentos funcionais para aumentar cAMP em uma célula de formação de osso; reduzir apoptose em uma célula de formação de osso; diminuir a relação de níveis de expressão de proteína Bax para proteína Bc1-2 em uma célula de formação de osso; aumentar o nível de expressão de uma ou mais de uma proteína de matriz de osso, um ativador transcricional, ou um regulador transcricional em uma célula de formação de osso; realçar a densidade mineral do osso, aumentar a massa óssea, diminuir a perda óssea, ou reduzir a incidência de fraturas de osso, ou qualquer combinação destes, em um indivíduo; também fornecidos são anticorpos voltados contra hormónio de paratíróide (PTH) preto urso e fragmentos funcionais destes.
BRPI0618469-3A 2005-11-10 2006-11-13 hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto BRPI0618469A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73614505P 2005-11-10 2005-11-10
PCT/US2006/060844 WO2007059470A2 (en) 2005-11-10 2006-11-13 Black bear parathyroid hormone and methods of using black bear parathyroid hormone

Publications (1)

Publication Number Publication Date
BRPI0618469A2 true BRPI0618469A2 (pt) 2011-08-30

Family

ID=38049379

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618469-3A BRPI0618469A2 (pt) 2005-11-10 2006-11-13 hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto

Country Status (9)

Country Link
US (1) US7994129B2 (pt)
EP (1) EP1945245A2 (pt)
JP (1) JP2009515535A (pt)
CN (1) CN101355959B (pt)
AU (1) AU2006315132A1 (pt)
BR (1) BRPI0618469A2 (pt)
CA (1) CA2628945A1 (pt)
IL (1) IL191250A0 (pt)
WO (1) WO2007059470A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2509996A1 (en) * 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4812304A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4822609A (en) 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US5420242A (en) 1986-10-22 1995-05-30 Kaare M. Gautvik Production of human parathyroid hormone from microorganisms
US5457092A (en) 1987-07-30 1995-10-10 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Methods of promoting bone growth in mammals comprising administration of modified parathyroid hormone
EP0341963A3 (en) 1988-05-09 1991-07-24 Merck & Co. Inc. Parathyroid hormone antagonists
US5744444A (en) 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
GB9020544D0 (en) 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
EP0559751B1 (en) 1990-11-26 1997-03-26 RECKER, Robert R. Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth)
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5208041A (en) 1991-05-23 1993-05-04 Allelix Biopharmaceuticals Inc. Essentially pure human parathyroid hormone
WO1993006846A1 (en) 1991-10-10 1993-04-15 Pang Peter K T Parathyroid hormone analogues and use in osteoporosis treatment
US5317010A (en) 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
JPH07502507A (ja) 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
DE4203040A1 (de) 1992-02-04 1993-08-05 Boehringer Mannheim Gmbh Neue parathormonfragmente, deren herstellung und diese enthaltende arzneimittel
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
AU672790B2 (en) 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
WO1994003201A1 (en) 1992-08-05 1994-02-17 Hilliker Sandra R Parathyroid hormone fragments and analogs
CZ286632B6 (cs) 1992-09-29 2000-05-17 Inhale Therapeutic Systems Farmaceutický prostředek
US6855337B1 (en) 1993-06-17 2005-02-15 Carle Development Foundation Bear derived isolate and method
WO1995002610A1 (en) 1993-07-13 1995-01-26 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
TW303299B (pt) 1993-07-22 1997-04-21 Lilly Co Eli
US5496801A (en) 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US6110892A (en) 1994-06-20 2000-08-29 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US5955425A (en) 1996-08-02 1999-09-21 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
CA2126299C (en) 1994-06-20 2000-12-12 Gordon E. Willick Parathyroid hormone analogues for the treatment of osteoporosis
CN1157566A (zh) 1994-09-09 1997-08-20 普罗克特和甘保尔公司 用于骨质疏松症的膦酸盐类和甲状旁腺激素
EP0779812A4 (en) 1994-09-09 1997-09-10 Procter & Gamble METHOD FOR TREATING OSTEOPOROSIS USING BONE-ACTIVE PHOSPHONATES AND PARATHORMONE
CN1158569A (zh) 1994-09-09 1997-09-03 普鲁克特和甘保尔公司 用于治疗骨质疏松症的雌激素和甲状腺素
JPH10511095A (ja) 1994-12-19 1998-10-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド 副甲状腺ホルモン又はその作動薬の低用量継続投与
US5747456A (en) 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
WO1996019206A1 (en) 1994-12-22 1996-06-27 Astra Aktiebolag Therapeutic preparation for inhalation containing parathyroïd hormone, pth
DE19517430A1 (de) 1995-05-12 1996-11-14 Boehringer Mannheim Gmbh Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
CA2178894A1 (en) * 1995-06-15 1996-12-16 Tsunehiko Fukuda Parathyroid hormone derivatives and their use
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
TW505654B (en) 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
CA2290443A1 (en) 1997-05-14 1998-11-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Peptide parathyroid hormone analogs
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US20020136779A1 (en) 1997-06-19 2002-09-26 Scil Diagnostics Gmbh Pharmaceutical compound preparation comprising a parathyroid hormone preparation and a calcium/phosphate preparation
EP1016412A4 (en) 1997-07-22 2001-05-02 Chugai Pharmaceutical Co Ltd DENTISTRY WITH PTH
KR100230578B1 (ko) 1997-07-25 1999-12-01 허영섭 포스포리불로키나제를 융합파트너로 이용하는 재조합 인간 부갑상선호르몬의 발현벡터
PL195703B1 (pl) 1997-09-09 2007-10-31 Hoffmann La Roche Zastosowanie polipeptydowego analogu peptydu pokrewnego hormonowi przytarczyc
AU9682098A (en) 1997-10-14 1999-05-03 Eli Lilly And Company Method of building and maintaining bone
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
EP0922467A3 (en) * 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
AU748271B2 (en) 1997-12-18 2002-05-30 Eli Lilly And Company Crystalline teriparatide
SE9801495D0 (sv) 1998-04-28 1998-04-28 Astra Ab Protein formulationa
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US20040033950A1 (en) 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
EP1119251A4 (en) 1998-10-07 2004-03-24 Univ Arkansas METHOD FOR SCREENING ON ANALOG BONE THERAPY ACTIVE SUBSTANCES THAT CONTROL APOPTOSIS AND THEIR USE
WO2000023594A1 (en) 1998-10-22 2000-04-27 The General Hospital Corporation BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
US6923968B2 (en) 2000-08-10 2005-08-02 Scantibodies Laboratory, Inc. Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis
US7893021B2 (en) 1999-06-02 2011-02-22 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
CA2387693A1 (en) 1999-09-20 2001-03-29 Eli Lilly And Company Method for monitoring treatment with a parathyroid hormone
EP1221966B1 (en) 1999-09-20 2005-11-16 Eli Lilly And Company Use of a parathyroid hormone for reducing the risk of cancer
US6316410B1 (en) 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2001023521A2 (en) 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
AU6788701A (en) 2000-06-30 2002-01-14 Suntory Ltd Medicinal components comprising human parathyroid hormone and medicinal compositions for nasal administration containing the components
US7226749B2 (en) 2000-12-05 2007-06-05 Zahradnik Richard J Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
PL211976B1 (pl) 2001-06-01 2012-07-31 Novartis Ag Kompozycja farmaceutyczna do podawania doustnego oraz zastosowanie kompozycji
JP4959917B2 (ja) 2001-08-17 2012-06-27 ノバルティス アーゲー 副甲状腺ホルモンフラグメント用経口送達剤としての５−ｃｎａｃ
WO2003024486A1 (fr) 2001-09-17 2003-03-27 Chugai Seiyaku Kabushiki Kaisha Traitements de la perte osseuse
US20040242489A1 (en) 2001-11-05 2004-12-02 Mitlak Bruce Howard Method for improving stability of a bone-connecting implant
JP2005525312A (ja) 2002-01-10 2005-08-25 オステオトロフィン エルエルシー 骨同化物質を用いた骨疾患の治療方法
EP1477496A4 (en) 2002-02-01 2006-08-02 Chugai Pharmaceutical Co Ltd PEG BINDING PTH OR PEG BINDING PTH DERIVATIVE
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
WO2003097690A2 (en) 2002-05-16 2003-11-27 Theratechnologies Inc. Pth derivatives resistant to skin proteases
AU2003251527A1 (en) 2002-06-13 2003-12-31 Beth Israel Deaconess Medical Center, Inc. Analogs of parathyroid hormone and pth-related protein as bone anabolic agents
US20050032698A1 (en) 2003-07-14 2005-02-10 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
EP1651246A4 (en) 2003-08-06 2009-06-24 Innophos Inc PROCESS FOR PROMOTING BONE GROWTH
US20050119183A1 (en) 2003-11-12 2005-06-02 Nps Allelix Corp. Method for treating bone loss using parathyroid hormone
EP1758927A4 (en) 2004-01-21 2008-09-17 Unigene Lab Inc PARATHYROID HORMONE AMIDE FRAGMENTS AND USES THEREOF
US20060127320A1 (en) 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060052305A1 (en) 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
EP1750756A2 (en) 2004-05-10 2007-02-14 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
BRPI0509788A (pt) 2004-05-13 2007-10-23 Alza Corp aparato e método para liberação transdérmica de agentes de hormÈnio paratireóides
CN1712066A (zh) 2004-06-22 2005-12-28 中国人民解放军军事医学科学院生物工程研究所 全长人甲状旁腺激素的新用途
ITMI20041440A1 (it) 2004-07-19 2004-10-19 Abiogen Pharma Spa Peptidi analoghi del pth-1-11
US20060069021A1 (en) 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US20060089723A1 (en) 2004-10-25 2006-04-27 Murphy Kieran P Method for bone augmentation
JP2006143603A (ja) 2004-11-16 2006-06-08 Asahi Kasei Pharma Kk 骨疾患治療用医薬複合剤

Also Published As

Publication number Publication date
WO2007059470A2 (en) 2007-05-24
CN101355959A (zh) 2009-01-28
US7994129B2 (en) 2011-08-09
US20070219132A1 (en) 2007-09-20
IL191250A0 (en) 2009-02-11
CA2628945A1 (en) 2007-05-24
AU2006315132A1 (en) 2007-05-24
JP2009515535A (ja) 2009-04-16
WO2007059470A3 (en) 2007-11-22
CN101355959B (zh) 2013-02-27
EP1945245A2 (en) 2008-07-23

Similar Documents

Publication Publication Date Title
NL301145I2 (nl) Tirbanibulin
TW200608961A (en) Methods and reagents for the treatment of metabolic disorders
MX348735B (es) Celulas madre mesenquimales que expresan los receptores tnf-alfa.
BR112017011067A2 (pt) cepas e métodos para a partição de energia em ruminantes
CL2013001138A1 (es) Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición.
EA200702433A1 (ru) Набухающий в воде гибридный материал с неорганическими добавками и способ его получения
MEP59208A (en) Activin-actriia antagonists and uses for promoting bone growth
NO20084380L (no) Neuromedin U-reseptoragonister og anvendelser derav
EA200600065A2 (ru) Гидрофобные композиционные и сыпучие материалы, их применение
BRPI0516727A (pt) métodos para tratar um linfoma positivo em cd30 , para inibir o crescimento de uma célula que expressa cd30, e para tratar ou prevenir uma doença
BR0306665A (pt) Uso de zeìna nativa para aperfeiçoamento do estado do cabelo e agentes
ECSP067014A (es) Modulación de producción de inmunoglobulina y trastornos atópicos
ECSP077222A (es) Anticuerpos monoclonales humanos contra interleucina-4 humana (il-4)
WO2008016648A3 (en) Certain chemical entities, compositions and methods
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
NO20073033L (no) Cytotoksiske midler innbefattende nye taksaner
BRPI0507194A (pt) processo para reduzir o conteúdo e cianeto de hidrogênio em misturas compreendendo penteno-nitrilas e cianeto e hidrogênio, e, uso de 1,3-butadieno
NO20093542L (no) Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer
BRPI0408410A (pt) arranjo de um ou mais elementos estruturais para uso em uma célula de eletrólise
EA201001224A1 (ru) Химические соединения, композиции и способы их использования
WO2007011757A8 (en) Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
BRPI0814452A2 (pt) Composição que contém um peptídeo penetrador em células, uso de uma composição farmacêutica e método de tratamento de um tumor
BR112022006784A2 (pt) Domínio extracelular modificado de receptor de fator estimulante de colônia de granulócito (g-csfr) e citocinas que se ligam ao mesmo
BRPI0618469A2 (pt) hormÈnio paratiróide de urso preto e métodos de uso de hormÈnio paratiróide de urso preto
TW200738255A (en) Methods of regulating renalase (Monoamine Oxidase C)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.